Page 2 - Ipca Laboratories
US FDA pulls up Ipca Labs for manufacturing violations at Gujarat plant
The United States Food and Drug Administration (USFDA) inspection of its Piparia (Silvassa) formulations manufacturing unit in August resulted in three observations, it added.
 "US FDA pulls up Ipca Labs for manufacturing violations at Gujarat plant")
Optimism on Europe, India biz to offset US sales losses for Ipca Labs
Analysts see 13.4% annual growth in domestic business over FY18-21
 "Optimism on Europe, India biz to offset US sales losses for Ipca Labs")
Ipca on recovery path over FDA clearance, growth in Africa tender business
The stock was trading at 17 times its 2020 earnings estimates
Ipca Labs hits 52-week high; up 21% in 11 days post Q3 results
The stock hit a 52-week high of Rs 671, up 5% on the BSE in otherwise weak market.
Ipca Laboratories acquires US-based API developer Pisgah Labs for $9.65 mn
Ipca Pharmaceutical Inc is a wholly-owned subsidiary while Onyx Scientific Ltd, UK (Onyx) is a step down subsidiary of the company
Hope of earnings recovery for Ipca Laboratories
Sorting out regulatory issues would lead to a re-rating
 "Hope of earnings recovery for Ipca Laboratories")
US FDA ban 'withdrawal of exemption' due to changed supply situation: Ipca
US FDA has not carried out any new inspection or re- inspection of the company's manufacturing units
 "US FDA ban 'withdrawal of exemption' due to changed supply situation: Ipca")
Regulatory issues put IPCA earnings at risk
The new action by the US regulator saw the stock lose a little more than 8%, to close at Rs 470.70
Ipca Labs nears 52-week low on USFDA bans import of drugs from three plants
The stock tanked 15% to Rs 437 on BSE in intra-day trade on back of heavy volumes
 "Ipca Labs nears 52-week low on USFDA bans import of drugs from three plants")
Ipca Labs shares up 4.5% as Q1 net profit rises twofold
Shares of Ipca Laboratories on Thursday rose 4.5 per cent, after the company reported over twofold jump in its standalone net profit at Rs 47.6 crore for the first quarter ended June, on account of robust sales.
 "Ipca Labs shares up 4.5% as Q1 net profit rises twofold")
Ipca Lab gains as Q1 profit more than doubles
At 12:34 pm, the stock was up 4% at Rs 524, after hitting low of Rs 494 on the BSE in intra-day trade.
Ipca: Investors should await clarity on FDA issues
India business continues to grow, but global trade holds the key
 "Ipca: Investors should await clarity on FDA issues")
The Global Fund stops sourcing anti-malaria drugs from Ipca
Move follows USFDA warning letter to three of Mumbai-based drug maker's plants; stock sheds 10%
 "The Global Fund stops sourcing anti-malaria drugs from Ipca")
